Intermittent fasting (IF) is being explored as a dietary intervention to mitigate AD-related effects, possibly by modulating factors such as reelin and <i>α</i>-synuclein, which are involved in synaptic function and AD pathology.<h4>Methods</h4>The study included six groups of rats: Ctrl, Ctrl.ADF, Ctrl.TRF, AD, AD.TRF, and AD.ADF. Here, RELN is linked to Alzheimer disease.